专家点评:T2DM合并肾损伤的传统治疗包括RAAS的抑制和糖脂等代谢因素的控制,而新型药物SGLT2i、GLP-1 RA、ns-MRA能在这些药物基础上进一步降低MACE和CV死亡风险,提示了代谢、纤维化、炎症机制的关键作用,以及针对这些残余风险靶点的有效性。2023年底AHA提出...
图2 SGLT2i、GLP-1 RA和ns-MRA联合应用于RAAS阻断剂治疗基线时50岁人群的2型糖尿病和UACR≥30 mg/g患者无MACE生存率 专家点评:T2DM合并肾损伤的传统治疗包括RAAS的抑制和糖脂等代谢因素的控制,而新型药物SGLT2i、GLP-1 RA、ns-MRA能...
The SGLT2i and GLP-1 RAs also reduced macroalbuminuria, decreased the time for doubling of serum creatinine, and slowed the time to end-stage renal disease. In this perspective, we review the potential benefit of combination SGLT2i/GLP-1 RA therapy on metabolic-cardiovascular-renal disease in...
与GLP-1受体激动剂相比,SGLT-2抑制剂-GLP-1受体激动剂联合使用可使主要不良心血管事件的风险降低30%(7.0 vs 10.3例事件/1000人年;风险比0.70,95%CI 0.49～0.99),严重肾脏事件风险降低57%(2.0 vs 4.6例事件/1000人年;风险比0.43,95%CI 0.23～0.80)。 与SGLT-2抑制剂相比,GLP-1受体激动剂-SGLT-2抑制剂联...
SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
在这项队列研究中,与单独使用任何一类药物相比,GLP-1受体激动剂-SGLT-2抑制剂联合使用发生主要不良心血管事件和严重肾脏事件的风险较低。 知识来源 [1] SIMMS-WILLIAMS N, TREVES N, YIN H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotranspor...
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes[ J]. Postgrad Med, 2017, 129(7): 686-697. 19. Pratley RE, Cersosimo E. Use of canagliflozin in combination with and compared to incretin-based therapies in type 2...
The combination of GLP-1 RAs with other therapeutic agents, such as SGLT-2 inhibitors and insulin, is another promising approach. Fixed-dose combinations could optimize outcomes, particularly for patients with advanced disease or those unresponsive to monotherapy. Moreover, increasing focus on pediatric...
The combination of GLP-1 RAs with other therapeutic agents, such as SGLT-2 inhibitors and insulin, is another promising approach. Fixed-dose combinations could optimize outcomes, particularly for patients with advanced disease or those unresponsive to monotherapy. Moreover, increasing focus on pediatric...
SGLT2 inhibitorGLP‐1 analoguestype 2 diabetesweight lossThis study aimed to observe the effect of the novel combination of dual add-on therapy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on glycaemic control and weight in...